SIONNA THERAPEUTICS INC (SION) — insider trading
Health Care · NASDAQ
SIONNA THERAPEUTICS INC (SION) has 52 reported SEC Form 4 insider transactions in our data, including 25 open-market sales among the most recent 52 (latest 2026-09-17).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-17 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market sale | 33,800 | $7.46 | $252.1K | Form 4 |
| 2026-09-17 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market sale | 3,415,011 | $6.32 | $21.58M | Form 4 |
| 2026-09-17 | Ridloff Elena | Officer (CFO and CBO) | Disposition to the issuer (derivative) | 165,440 | — | $0 | Form 4 |
| 2026-09-17 | Ridloff Elena | Officer (CFO and CBO) | Grant / award / vesting (derivative) | 165,440 | — | $0 | Form 4 |
| 2026-09-17 | Ridloff Elena | Officer (CFO and CBO) | Grant / award / vesting | 47,268 | — | $0 | Form 4 |
| 2026-09-17 | Ridloff Elena | Officer (CFO and CBO) | Grant / award / vesting | 47,269 | — | $0 | Form 4 |
| 2026-09-17 | McKee Charlotte | Officer (CMO and Head of R&D) | Disposition to the issuer (derivative) | 155,700 | — | $0 | Form 4 |
| 2026-09-17 | McKee Charlotte | Officer (CMO and Head of R&D) | Grant / award / vesting (derivative) | 155,700 | — | $0 | Form 4 |
| 2026-09-17 | McKee Charlotte | Officer (CMO and Head of R&D) | Grant / award / vesting | 50,000 | — | $0 | Form 4 |
| 2026-09-17 | McKee Charlotte | Officer (CMO and Head of R&D) | Grant / award / vesting | 50,000 | — | $0 | Form 4 |
| 2026-09-17 | Fitzpatrick Jennifer | Officer (CLO and Head of Program Mgmt.) | Disposition to the issuer (derivative) | 103,140 | — | $0 | Form 4 |
| 2026-09-17 | Fitzpatrick Jennifer | Officer (CLO and Head of Program Mgmt.) | Grant / award / vesting (derivative) | 103,140 | — | $0 | Form 4 |
| 2026-09-17 | Fitzpatrick Jennifer | Officer (CLO and Head of Program Mgmt.) | Grant / award / vesting | 28,132 | — | $0 | Form 4 |
| 2026-09-17 | Fitzpatrick Jennifer | Officer (CLO and Head of Program Mgmt.) | Grant / award / vesting | 28,133 | — | $0 | Form 4 |
| 2026-09-17 | Cloonan Michael | Director, Officer (President & CEO) | Disposition to the issuer (derivative) | 436,100 | — | $0 | Form 4 |
| 2026-09-17 | Cloonan Michael | Director, Officer (President & CEO) | Grant / award / vesting (derivative) | 436,100 | — | $0 | Form 4 |
| 2026-09-17 | Cloonan Michael | Director, Officer (President & CEO) | Grant / award / vesting | 109,025 | — | $0 | Form 4 |
| 2026-09-17 | Cloonan Michael | Director, Officer (President & CEO) | Grant / award / vesting | 109,025 | — | $0 | Form 4 |
| 2026-07-07 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | Director | Open-market sale | 85,918 | $44.86 | $3.85M | Form 4 |
| 2026-07-07 | Thompson Peter A. | Director | Open-market sale | 85,918 | $44.86 | $3.85M | Form 4 |
| 2026-07-06 | Fitzpatrick Jennifer | Officer (Chief Legal Officer) | Option exercise / conversion (derivative) | 10,250 | — | $0 | Form 4 |
| 2026-07-06 | Fitzpatrick Jennifer | Officer (Chief Legal Officer) | Open-market sale | 10,250 | $43.60 | $446.9K | Form 4 |
| 2026-07-06 | Fitzpatrick Jennifer | Officer (Chief Legal Officer) | Option exercise / conversion | 10,250 | $6.11 | $62.6K | Form 4 |
| 2026-06-30 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | Director | Open-market sale | 115,844 | $45.50 | $5.27M | Form 4 |
| 2026-06-30 | Thompson Peter A. | Director | Open-market sale | 115,844 | $45.50 | $5.27M | Form 4 |
| 2026-06-17 | Booth Bruce | Director | Grant / award / vesting (derivative) | 17,340 | — | $0 | Form 4 |
| 2026-06-17 | Clancy Paul J | Director | Grant / award / vesting (derivative) | 17,340 | — | $0 | Form 4 |
| 2026-06-17 | Fleming Harold Edward | Director | Grant / award / vesting (derivative) | 17,340 | — | $0 | Form 4 |
| 2026-06-17 | Resnick Joshua | Director | Grant / award / vesting (derivative) | 17,340 | — | $0 | Form 4 |
| 2026-06-17 | Ruddy Marcella K. | Director | Grant / award / vesting (derivative) | 17,340 | — | $0 | Form 4 |
| 2026-06-17 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Grant / award / vesting (derivative) | 17,340 | — | $0 | Form 4 |
| 2026-06-17 | Thompson Peter A. | Director | Grant / award / vesting (derivative) | 17,340 | — | $0 | Form 4 |
| 2026-06-17 | Viney Joanne L. | Director | Grant / award / vesting (derivative) | 17,340 | — | $0 | Form 4 |
| 2026-06-17 | Stelzer Laurie | Director | Grant / award / vesting (derivative) | 17,340 | — | $0 | Form 4 |
| 2026-05-27 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | Director | Open-market sale | 101 | $44.49 | $4.5K | Form 4 |
| 2026-05-27 | Thompson Peter A. | Director | Open-market sale | 101 | $44.49 | $4.5K | Form 4 |
| 2026-05-11 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | Director | Open-market sale | 184,639 | $46.22 | $8.53M | Form 4 |
| 2026-05-11 | Thompson Peter A. | Director | Open-market sale | 184,639 | $46.22 | $8.53M | Form 4 |
| 2026-05-08 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | Director | Open-market sale | 59,767 | $44.58 | $2.66M | Form 4 |
| 2026-05-08 | Thompson Peter A. | Director | Open-market sale | 59,767 | $44.58 | $2.66M | Form 4 |
| 2026-05-07 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | Director | Open-market sale | 48,546 | $44.61 | $2.17M | Form 4 |
| 2026-05-07 | Thompson Peter A. | Director | Open-market sale | 48,546 | $44.61 | $2.17M | Form 4 |
| 2026-04-18 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | Director | Open-market sale | 2,948 | $44.52 | $131.2K | Form 4 |
| 2026-04-18 | Thompson Peter A. | Director | Open-market sale | 2,948 | $44.52 | $131.2K | Form 4 |
| 2026-04-17 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | Director | Open-market sale | 52,397 | $44.68 | $2.34M | Form 4 |
| 2026-04-17 | Thompson Peter A. | Director | Open-market sale | 52,397 | $44.68 | $2.34M | Form 4 |
| 2026-04-16 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | Director | Open-market sale | 226,906 | $45.34 | $10.29M | Form 4 |
| 2026-04-16 | Thompson Peter A. | Director | Open-market sale | 226,906 | $45.34 | $10.29M | Form 4 |
| 2026-04-15 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | Director | Open-market sale | 235,863 | $44.64 | $10.53M | Form 4 |
| 2026-04-15 | Thompson Peter A. | Director | Open-market sale | 235,863 | $44.64 | $10.53M | Form 4 |
| 2026-04-14 | ORBIMED ADVISORS LLC; OrbiMed Capital GP VIII LLC | Director | Open-market sale | 47,814 | $44.51 | $2.13M | Form 4 |
| 2026-04-14 | Thompson Peter A. | Director | Open-market sale | 47,814 | $44.51 | $2.13M | Form 4 |
Ask the chat about SION's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: SIONNA THERAPEUTICS INC (SION).
Last updated 2026-09-17 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.